IDEXX Laboratories Inc
NASDAQ:IDXX

Watchlist Manager
IDEXX Laboratories Inc Logo
IDEXX Laboratories Inc
NASDAQ:IDXX
Watchlist
Price: 417.24 USD -0.31% Market Closed
Market Cap: 34.2B USD
Have any thoughts about
IDEXX Laboratories Inc?
Write Note

IDEXX Laboratories Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IDEXX Laboratories Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
IDEXX Laboratories Inc
NASDAQ:IDXX
Current Portion of Long-Term Debt
$99.1m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Current Portion of Long-Term Debt
$2.2B
CAGR 3-Years
63%
CAGR 5-Years
11%
CAGR 10-Years
27%
Boston Scientific Corp
NYSE:BSX
Current Portion of Long-Term Debt
$1.7B
CAGR 3-Years
85%
CAGR 5-Years
5%
CAGR 10-Years
88%
Stryker Corp
NYSE:SYK
Current Portion of Long-Term Debt
$2.2B
CAGR 3-Years
361%
CAGR 5-Years
33%
CAGR 10-Years
11%
Abbott Laboratories
NYSE:ABT
Current Portion of Long-Term Debt
$1.6B
CAGR 3-Years
29%
CAGR 5-Years
5%
CAGR 10-Years
23%
Intuitive Surgical Inc
NASDAQ:ISRG
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

IDEXX Laboratories Inc
Glance View

Market Cap
34.3B USD
Industry
Health Care

IDEXX Laboratories Inc. is a leading global provider of veterinary diagnostic products and services, dedicated to enhancing the health and well-being of pets worldwide. Founded in 1983, the company has established itself as an innovator in the animal healthcare market, offering a comprehensive range of diagnostic tests, equipment, and software that empower veterinarians to make informed decisions. With a consistent focus on research and development, IDEXX has expanded its portfolio to include cutting-edge solutions such as digital imaging and telemedicine, addressing the growing needs of the pet care industry. Their strategic partnerships and robust distribution channels further bolster their presence in both developed and emerging markets. For investors, IDEXX represents a compelling opportunity within a steadily growing sector. The company's recurring revenue model, driven by its suite of diagnostic tests and subscriptions to software solutions, ensures stable cash flow and predictability in earnings. IDEXX has also demonstrated impressive financial performance, characterized by strong revenue growth, high profit margins, and a commitment to shareholder returns. By harnessing trends in pet ownership and increasing expenditures on pet healthcare, IDEXX positions itself as a reliable player in the marketplace. With its dedication to innovation, customer service, and global expansion, IDEXX Laboratories Inc. stands poised for sustained growth, making it an attractive consideration for long-term investors.

IDXX Intrinsic Value
252.54 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is IDEXX Laboratories Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
99.1m USD

Based on the financial report for Sep 30, 2024, IDEXX Laboratories Inc's Current Portion of Long-Term Debt amounts to 99.1m USD.

What is IDEXX Laboratories Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
10%

Over the last year, the Current Portion of Long-Term Debt growth was -34%. The average annual Current Portion of Long-Term Debt growth rates for IDEXX Laboratories Inc have been 10% over the past three years .

Back to Top